341 related articles for article (PubMed ID: 18709565)
21. Pitfalls in the diagnosis of biallelic PMS2 mutations.
Antelo M; Milito D; Rhees J; Roca E; Barugel M; Cuatrecasas M; Moreira L; Leoz ML; Carballal S; Ocaña T; Pellisé M; Castells A; Boland CR; Goel A; Balaguer F
Fam Cancer; 2015 Sep; 14(3):411-4. PubMed ID: 25773960
[TBL] [Abstract][Full Text] [Related]
22. Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome.
Tamura K; Kaneda M; Futagawa M; Takeshita M; Kim S; Nakama M; Kawashita N; Tatsumi-Miyajima J
Int J Clin Oncol; 2019 Sep; 24(9):999-1011. PubMed ID: 31273487
[TBL] [Abstract][Full Text] [Related]
23. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
[TBL] [Abstract][Full Text] [Related]
24. Multiple pilomatricomas with somatic CTNNB1 mutations in children with constitutive mismatch repair deficiency.
Chmara M; Wernstedt A; Wasag B; Peeters H; Renard M; Beert E; Brems H; Giner T; Bieber I; Hamm H; Sciot R; Wimmer K; Legius E
Genes Chromosomes Cancer; 2013 Jul; 52(7):656-64. PubMed ID: 23629955
[TBL] [Abstract][Full Text] [Related]
25. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III?
Felton KE; Gilchrist DM; Andrew SE
Clin Genet; 2007 Jun; 71(6):499-500. PubMed ID: 17539898
[TBL] [Abstract][Full Text] [Related]
26. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
Shuen AY; Lanni S; Panigrahi GB; Edwards M; Yu L; Campbell BB; Mandel A; Zhang C; Zhukova N; Alharbi M; Bernstein M; Bowers DC; Carroll S; Cole KA; Constantini S; Crooks B; Dvir R; Farah R; Hijiya N; George B; Laetsch TW; Larouche V; Lindhorst S; Luiten RC; Magimairajan V; Mason G; Mason W; Mordechai O; Mushtaq N; Nicholas G; Oren M; Palma L; Pedroza LA; Ramdas J; Samuel D; Wolfe Schneider K; Seeley A; Semotiuk K; Shamvil A; Sumerauer D; Toledano H; Tomboc P; Wierman M; Van Damme A; Lee YY; Zapotocky M; Bouffet E; Durno C; Aronson M; Gallinger S; Foulkes WD; Malkin D; Tabori U; Pearson CE
J Clin Oncol; 2019 Feb; 37(6):461-470. PubMed ID: 30608896
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
28. Biallelic PMS2 mutations and a distinctive childhood cancer syndrome.
Tan TY; Orme LM; Lynch E; Croxford MA; Dow C; Dewan PA; Lipton L
J Pediatr Hematol Oncol; 2008 Mar; 30(3):254-7. PubMed ID: 18376293
[TBL] [Abstract][Full Text] [Related]
29. Germline mutation and protein expression analysis of mismatch repair genes MSH6 and PMS2 in Malaysian Lynch syndrome patients.
Zahary MN; Kaur G; Hassan MR; Sidek AS; Singh H; Yeh LY; Ankathil R
Int J Colorectal Dis; 2014 Feb; 29(2):261-2. PubMed ID: 24072394
[No Abstract] [Full Text] [Related]
30. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.
Drost M; Koppejan H; de Wind N
Hum Mutat; 2013 Nov; 34(11):1477-80. PubMed ID: 24027009
[TBL] [Abstract][Full Text] [Related]
32. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort.
Lavoine N; Colas C; Muleris M; Bodo S; Duval A; Entz-Werle N; Coulet F; Cabaret O; Andreiuolo F; Charpy C; Sebille G; Wang Q; Lejeune S; Buisine MP; Leroux D; Couillault G; Leverger G; Fricker JP; Guimbaud R; Mathieu-Dramard M; Jedraszak G; Cohen-Hagenauer O; Guerrini-Rousseau L; Bourdeaut F; Grill J; Caron O; Baert-Dusermont S; Tinat J; Bougeard G; Frébourg T; Brugières L
J Med Genet; 2015 Nov; 52(11):770-8. PubMed ID: 26318770
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
[TBL] [Abstract][Full Text] [Related]
34. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome.
Durno CA; Sherman PM; Aronson M; Malkin D; Hawkins C; Bakry D; Bouffet E; Gallinger S; Pollett A; Campbell B; Tabori U;
Eur J Cancer; 2015 May; 51(8):977-83. PubMed ID: 25883011
[TBL] [Abstract][Full Text] [Related]
36. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor.
Plaschke J; Linnebacher M; Kloor M; Gebert J; Cremer FW; Tinschert S; Aust DE; von Knebel Doeberitz M; Schackert HK
Eur J Hum Genet; 2006 May; 14(5):561-6. PubMed ID: 16418736
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
Peltomäki P
Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
[TBL] [Abstract][Full Text] [Related]
38. PMS2 involvement in patients suspected of Lynch syndrome.
Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
[TBL] [Abstract][Full Text] [Related]
39. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
40. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
